Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).

被引：0
|
作者：
Cremolini, Chiara
Loupakis, Fotios
Yang, Dongyun
Salvatore, Lisa
Zhang, Wu
Wakatsuki, Takeru
Schirripa, Marta
Lonardi, Sara
Antoniotti, Carlotta
Aprile, Giuseppe
Masi, Gianluca
Graziano, Francesco
Ruzzo, Annamaria
Lucchesi, Sara
Ronzoni, Monica
Maus, Martin Karl Herbert
Bocci, Guido
Tonini, Giuseppe
Falcone, Alfredo
Lenz, Heinz-Josef
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med 2, Ist Toscano Tumori, Pisa, Italy
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] IRCCS, Ist Oncolog Veneto, Padua, Italy
[4] Azienda Osped Univ Udine, Udine, Italy
[5] UOC Oncol AO, Pesaro, Italy
[6] Univ Urbino, Sect Biochem & Mol Biol, Dept Biomol Sci, I-61029 Urbino, Italy
[7] Osped Pontedera, UO Oncol Med, Pontedera, Italy
[8] Ist Sci San Raffaele, Dipartimento Oncol, Milan, Italy
[9] Response Genet Inc, Los Angeles, CA USA
[10] Univ Pisa, Div Chemotherapy & Pharmacol, Dept Internal Med, Pisa, Italy
[11] Univ Campus Biomed, Rome, Italy
[12] Univ Pisa, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PROSPECTIVE EVALUATION OF CANDIDATE SNPS OF VEGF/VEGFR PATHWAY IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV)
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuky, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Maus, Martin
    Bocci, Guido
    Falcone, Alfredo
    Lenz, Heinz Joseph
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 105 - 106
  • [2] Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
    Loupakis, Fotios
    Cremolini, Chiara
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuki, Takeru
    Bohanes, Pierre
    Schirripa, Marta
    Benhaim, Leonor
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Ronzoni, Monica
    De Vita, Ferdinando
    Tonini, Giuseppe
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. PLOS ONE, 2013, 8 (07):
  • [3] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [4] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [5] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [6] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
    Muro, Kei
    Yamanaka, Takeharu
    Suenaga, Mitsukuni
    Nishina, Tomohiro
    Yasul, Hisateru
    Ura, Takashi
    Denda, Tadamichi
    Ikeda, Junichi
    Esakl, Taito
    Nishisaki, Hogara
    Takano, Yoshinao
    Kondo, Ken
    Takeda, Koji
    Takahashi, Yasuo
    Endo, Kazuya
    Sugiyama, Yasuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Effectiveness and Safety of Bevacizumab(BV) plus FOLFIRI as First-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study
    Fourrier-Reglat, A.
    Rouyer, M.
    Benichou, J.
    Balestra, A.
    Bernard, M. A.
    Grelaud, A.
    Smith, D.
    Ravaud, A.
    Moore, N.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S28 - S28
  • [8] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    [J]. CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
  • [9] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lima, C. S. Rocha
    Baranda, J. C.
    Wallmark, J.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [10] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
12345